Breast cancer in China
China approved trastuzumab rezetecan, a Hengrui HER2 antibody-drug conjugate, in March 2026 for HER2-positive advanced breast cancer after prior anti-HER2 therapy; it is not FDA-approved. Surgery, chemotherapy and radiotherapy are standard at tertiary cancer hospitals, with access through oncology departments or trials.
VerifiedLast verified
Treatments available
| Treatments | Status in China | Status in US | Sources |
|---|---|---|---|
| Trastuzumab rezetecan (SHR-A1811), HER2 ADC | Approved in China | Not approved | Jiangsu Hengrui / HKEXnews |
Hospitals with documented programs
Informational listings from cited public sources, not recommendations.
ShanghaiFudan University Shanghai Cancer Center复旦大学附属肿瘤医院International deptReported
HangzhouZhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences)浙江省肿瘤医院（中国科学院大学附属肿瘤医院）No public intl deptVerified
BeijingPeking Union Medical College Hospital (PUMCH), International Medical Services北京协和医院 国际医疗部International deptVerified
BeijingBeijing United Family Hospital北京和睦家医院International deptJCIVerified
BeijingPeking University Cancer Hospital (Beijing Cancer Hospital)北京大学肿瘤医院No public intl deptVerified
GuangzhouSun Yat-sen University Cancer Center中山大学肿瘤防治中心International deptVerified
Hainan / Boao LechengRuijin Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Boao Research Hospital)上海交通大学医学院附属瑞金医院海南医院（海南博鳌研究型医院）International deptReported
Clinical trials
658studies listed as recruiting with a site in China on ClinicalTrials.gov, as of 2026-10-26. See the list
We link trials only; enrollment decisions belong to trial teams. Since May 2026, charging patients to join clinical research is prohibited in China, as reported by AFP.
Frequently asked
What is trastuzumab rezetecan's status for breast cancer?
NMPA approved it in March 2026 for adults with locally advanced or metastatic HER2-positive breast cancer previously treated with one or more anti-HER2 drugs. HER2-low results were presented at ESMO in October 2026; it is not FDA-approved.
[1] Jiangsu Hengrui / HK…[2] MedPage TodayAre breast cancer trials recruiting in China?
ClinicalTrials.gov listed 658 recruiting studies with a China site for breast cancer on 2026-10-26.
[1] ClinicalTrials.gov (…Sources
- Hengrui announcement: trastuzumab rezetecan approved for HER2-positive breast cancer
“This product is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapies.”
Information only. Not medical advice, diagnosis or a treatment recommendation. Talk to your doctor. In an emergency, call your local emergency number.